Search results
Results from the WOW.Com Content Network
Luxdegalutamide, also known as ARV-766, is an investigational oral androgen receptor (AR) degrader being developed by Arvinas for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Craig M. Crews (born June 1, 1964) is an American scientist at Yale University known for his contributions to chemical biology.He is known for his contributions to the field of induced proximity through his work in creating heterobifunctional molecules that "hijack" cellular processes by inducing the interaction of two proteins inside a living cell. [1]
Biotech and pharmaceutical companies in the New York metropolitan area represent a significant and growing economic component of the New York metropolitan area, [1] [2] the most populous combined statistical area in the United States [3] and one of the most populous megacities in the world.
We also expect readouts for VERITAC 2 of ER PROTAC we co-developing with Arvinas for ER+ second-line plus methodic breast cancer and potentially for Crest which is a Sasanlimab, a differentiated ...
This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.
DelveInsight’s 'Adenosine Antagonists Pipeline Insight 2024' report provides comprehensive global coverage of pipeline adenosine antagonists in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the adenosine antagonists pipeline domain.
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
Arena Pharmaceuticals Inc. is an American biopharmaceutical company founded in 1997 and headquartered in San Diego, California. Arena focused on discovering drugs that act on G protein-coupled receptors (GPCRs). The company developed technology it called Constitutively Activated Receptor Technology (CART) that identified drug leads targeting ...